Treatment of age-related macular degeneration: focus on ranibizumab

Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter SzurmanTuebingen University Eye Center, University of Tuebingen, GermanyAbstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A, significantly slows down loss of vision and causes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter Szurman
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/808111db7fc941a4b85f538425fd4db2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:808111db7fc941a4b85f538425fd4db2
record_format	dspace
spelling	oai:doaj.org-article:808111db7fc941a4b85f538425fd4db22021-12-02T04:07:14ZTreatment of age-related macular degeneration: focus on ranibizumab1177-54671177-5483https://doaj.org/article/808111db7fc941a4b85f538425fd4db22008-03-01T00:00:00Zhttp://www.dovepress.com/treatment-of-age-related-macular-degeneration-focus-on-ranibizumab-a360https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter SzurmanTuebingen University Eye Center, University of Tuebingen, GermanyAbstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A, significantly slows down loss of vision and causes significant visual improvement in many patients with choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). These benefits of intravitreal ranibizumab apply to all angiographic subtypes of neovascular AMD and across all lesion sizes when the drug is injected at monthly intervals as shown in two pivotal phase III trials (ANCHOR and MARINA). The results from the PrONTO study suggest that less frequent treatment with ranibizumab through a variable dosing regimen dependent on optical coherence tomography (OCT) findings is a treatment option that results in comparably favorable visual outcomes. Currently, it is unclear whether combination therapy of ranibizumab with photodynamic therapy (PDT) provides any significant advantage over ranibizumab monotherapy (FOCUS trial); however, the combination of PDT and ranibizumab may decrease the need for frequent retreatment. This question will be addressed in the SUMMIT trial. Therapy with ranibizumab is generally very well tolerated with a low rate of seriously adverse ocular events or systemic side-effects. The advent of vascular endothelial growth factor (VEGF) inhibitors has revolutionized the therapy of neovascular AMD. Ranibizumab at the moment appears to be the most effective approved treatment for neovascular AMD.Keywords: Lucentis, ranibizumab, vascular endothelial growth factor (VEGF), age-related macular degeneration (AMD), neovascular, exudative AMD, treatment Martin S SpitzerFocke ZiemssenKarl U Bartz-SchmidtFaik GeliskenPeter SzurmanDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 1, Pp 1-14 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Martin S Spitzer Focke Ziemssen Karl U Bartz-Schmidt Faik Gelisken Peter Szurman Treatment of age-related macular degeneration: focus on ranibizumab
description	Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter SzurmanTuebingen University Eye Center, University of Tuebingen, GermanyAbstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A, significantly slows down loss of vision and causes significant visual improvement in many patients with choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). These benefits of intravitreal ranibizumab apply to all angiographic subtypes of neovascular AMD and across all lesion sizes when the drug is injected at monthly intervals as shown in two pivotal phase III trials (ANCHOR and MARINA). The results from the PrONTO study suggest that less frequent treatment with ranibizumab through a variable dosing regimen dependent on optical coherence tomography (OCT) findings is a treatment option that results in comparably favorable visual outcomes. Currently, it is unclear whether combination therapy of ranibizumab with photodynamic therapy (PDT) provides any significant advantage over ranibizumab monotherapy (FOCUS trial); however, the combination of PDT and ranibizumab may decrease the need for frequent retreatment. This question will be addressed in the SUMMIT trial. Therapy with ranibizumab is generally very well tolerated with a low rate of seriously adverse ocular events or systemic side-effects. The advent of vascular endothelial growth factor (VEGF) inhibitors has revolutionized the therapy of neovascular AMD. Ranibizumab at the moment appears to be the most effective approved treatment for neovascular AMD.Keywords: Lucentis, ranibizumab, vascular endothelial growth factor (VEGF), age-related macular degeneration (AMD), neovascular, exudative AMD, treatment
format	article
author	Martin S Spitzer Focke Ziemssen Karl U Bartz-Schmidt Faik Gelisken Peter Szurman
author_facet	Martin S Spitzer Focke Ziemssen Karl U Bartz-Schmidt Faik Gelisken Peter Szurman
author_sort	Martin S Spitzer
title	Treatment of age-related macular degeneration: focus on ranibizumab
title_short	Treatment of age-related macular degeneration: focus on ranibizumab
title_full	Treatment of age-related macular degeneration: focus on ranibizumab
title_fullStr	Treatment of age-related macular degeneration: focus on ranibizumab
title_full_unstemmed	Treatment of age-related macular degeneration: focus on ranibizumab
title_sort	treatment of age-related macular degeneration: focus on ranibizumab
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/808111db7fc941a4b85f538425fd4db2
work_keys_str_mv	AT martinsspitzer treatmentofagerelatedmaculardegenerationfocusonranibizumab AT fockeziemssen treatmentofagerelatedmaculardegenerationfocusonranibizumab AT karlubartzschmidt treatmentofagerelatedmaculardegenerationfocusonranibizumab AT faikgelisken treatmentofagerelatedmaculardegenerationfocusonranibizumab AT peterszurman treatmentofagerelatedmaculardegenerationfocusonranibizumab
_version_	1718401440951566336

Treatment of age-related macular degeneration: focus on ranibizumab

Ejemplares similares